This invention relates to pyrazole compounds or pharmaceutically acceptable salts thereof. Compounds of this invention are inhibitors of methionine aminopeptidase 2 (MetAP2) and dipeptidyl peptidase-4 (DPP-4). MetAP2 is a metalloproteinase that cleaves initiator methionine from nascent peptide emerging from the ribosomes. WO 2010/065879 reports small molecule MetAP2 inhibitors for obesity treatment. DPP-4 inhibitors are an established drug class to improve glycemic control in patients with type 2 diabetes mellitus. Compounds with dual inhibitory activity in both MetAP2 and DPP-4 are desired. The present invention provides novel compounds with dual MetAP2 and DPP-4 inhibitition. These dual inhibitor compounds can be useful in the treatment of a MetAP2 and DPP-4 mediated condition. The present invention provides a compound of the following Formula (I)； or a pharmaceutically acceptable salt thereof. In an embodiment of the invention, the compound is
